AREVA Nuclear Medicine Efforts Recognized by the Clinton Global Initiative

AREVA, through its subsidiary AREVA Med LLC, announced today that the Clinton Global Initiative has recognized its efforts to develop innovative production methods to produce medical-grade Lead-212. This one is used in promising alpha radio-immunotherapy treatments, to combat cancer.

Since the signature of a cooperation and research agreement with the U.S. National Cancer Institute and the University of Alabama, AREVA Med has increased its efforts to demonstrate the benefits of the medical grade lead-212.

Relying on its long experience in radiochemistry and nuclear engineering, AREVA has developed new processes to extract rare isotopes derived from its industrial activities.

AREVA CEO Anne Lauvergeon said: "On behalf of all AREVA employees, I am honored that our efforts in nuclear medicine have been recognized by the renowned Clinton Global Initiative, which supports projects that are innovative and beneficial for people at a global scale. This recognition demonstrates our spirit of commitment worldwide. It is also a tribute to our American partners, including the U.S. National Cancer Institute and the University of Alabama at Birmingham."